Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses: 2021-2025

Historic Other Operating Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $83.6 million.

  • Kiniksa Pharmaceuticals International's Other Operating Expenses rose 69.10% to $83.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year increase of 88.65%. This contributed to the annual value of $189.2 million for FY2024, which is 110.41% up from last year.
  • Kiniksa Pharmaceuticals International's Other Operating Expenses amounted to $83.6 million in Q3 2025, which was up 17.66% from $71.0 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Other Operating Expenses ranged from a high of $83.6 million in Q3 2025 and a low of $2.5 million during Q2 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Other Operating Expenses value was $42.3 million (recorded in 2024), while the average stood at $45.0 million.
  • Data for Kiniksa Pharmaceuticals International's Other Operating Expenses shows a peak YoY spiked of 317.78% (in 2022) over the last 5 years.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Other Operating Expenses (Quarterly) stood at $4.7 million in 2021, then surged by 202.68% to $14.2 million in 2022, then surged by 86.36% to $26.5 million in 2023, then surged by 149.16% to $66.1 million in 2024, then soared by 69.10% to $83.6 million in 2025.
  • Its Other Operating Expenses stands at $83.6 million for Q3 2025, versus $71.0 million for Q2 2025 and $61.7 million for Q1 2025.